MétaCan
Menu
Back to cohort
Record W7117318535 · doi:10.1002/alz70859_103791

The Emory‐Sage‐SGC‐JAX TREAT‐AD Center: Developing Resources for Alzheimer’s Disease Novel Targets

2025· article· en· W7117318535 on OpenAlexaff
Karina Leal, Elizabeth Zoeller, Gregory A. Cary, Jesse C. Wiley, Yuhong Du, Levon Halabelian, Ranjita Betarbet, Gregory W Carter, Haian Fu, Frank M. Longo, Stacey J Sukoff Rizzo, Aled M Edwards, Allan I. Levey

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicCholinesterase and Neurodegenerative Diseases
Canadian institutionsStructural Genomics ConsortiumUniversity of Toronto
Fundersnot available
KeywordsDiseasePortfolioProperty (philosophy)Resource (disambiguation)Information resourceMEDLINE

Abstract

fetched live from OpenAlex

BACKGROUND: Alzheimer's Disease (AD) is a debilitating neurodegenerative disorder affecting an estimated 55 million people world-wide. With no clear understanding of disease mechanism, hypothesis-based AD drug discovery has proven to be a high-risk endeavor. The TREAT-AD Consortium was initiated to improve, diversify, and reinvigorate the AD drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets. To this end, the Emory-Sage-SGC-JAX TREAT-AD Center adopted the concept of a target enabling package (TEP) to bridge the gap between target discovery and new therapeutics and to stimulate drug discovery by catalyzing investigation across the field for potential therapeutic pathways. Our aim is to allow for rapid exploration of emerging therapeutic hypotheses and novel AD therapeutic targets, including those emanating from the NIA-funded target discovery programs in AD, and initiate early-stage drug discovery campaigns against the enabled targets. METHOD: Given the demonstrated heterogeneity of AD in biological and genetic components, it is critical to identify new therapeutic approaches. Our Center developed an iterative target prioritization pipeline to score candidate proteins and organize groups of co-functional proteins into standardized therapeutic hypotheses for validation. Nominated targets were evaluated by calculating an unbiased target AD risk score that is then mapped to 19 biological domains that describe and codify the different processes that are dysregulated in AD. Targets that meet criteria for development are evaluated to identify a set of experimental reagents necessary for hypothesis testing. RESULT: Our center has developed TEPs for more than 50 understudied targets. For each prioritized target, a TEP may include bioinformatic analysis, expression constructs, purified protein and methods, validated knockout cell lines, antibody validation, assay development, crystal structures, screening, and probe development. All reagents are developed to meet established quality criteria. Advanced targets include DHX58, SYK, DDX1, SDC4, CAPN1, ARHGEF2, and members of 'Module 42' including SMOC1. CONCLUSION: All data, protocols, reagent sets, and chemical tools are made widely available on the AD Knowledge Portal with no intellectual property claims. Target Risk Scores and biodomains are accessible through Agora. For more information and the full target portfolio see www.treatad.org.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.025
Threshold uncertainty score0.085

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0060.006
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0040.003
Open science0.0030.005
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0250.020

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.322
Teacher spread0.279 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicCholinesterase and Neurodegenerative DiseasesFrench-language works237,207